絞り込み

16546

広告

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

著者 Hochmair MJ , Morabito A , Hao D , Yang CT , Soo RA , Yang JC , Gucalp R , Halmos B , Wang L , Golembesky A , Märten A , Cufer T
Future Oncol.2018 Oct 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (39view , 1users)

Full Text Sources

Miscellaneous

To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment.
PMID: 30336693 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード